Migraine and CGRP inhibitors

From a western clinical standpoint, migraine arises when the trigeminovascular system becomes hyperexcitable. Peripheral trigeminal afferents release neuropeptides, prominently calcitonin gene–related peptide (CGRP). CGRP binds to receptors on vascular smooth muscle and meningeal immune cells, producing vasodilation, mast cell activation, and a feed-forward loop of neuronal sensitization that propagates pain. Elevated CGRP during attacks and normalization after effective therapy, alongside the ability of CGRP infusion to trigger migraine-like headaches, firmly implicate this peptide in attack biology. People with chronic migraine and those with prominent central sensitization features (e.g., cutaneous allodynia) often show higher interictal CGRP levels, suggesting sustained pathway upregulation. Targeting this pathway has reshaped prevention and acute care. Monoclonal antibodies against the CGRP ligand (galcanezumab, fremanezumab, eptinezumab) or its receptor (erenumab) are administered monthly or quarterly. Across pivotal trials, they reduce monthly migraine days by roughly 1–2 more than placebo and increase the odds of 50% response by about 10–20% over placebo. Onset is frequently observed within the first 1–4 weeks, and eptinezumab has shown day-1 onset after infusion. Small-molecule CGRP receptor antagonists—ubrogepant and rimegepant for acute treatment, zavegepant as an intranasal acute option, and atogepant for prevention—provide 2-hour pain freedom and symptom relief rates superior to placebo and yield modest preventive gains. Safety profiles are favorable compared with many traditional preventives. Common adverse effects include injection-site reactions and constipation with mAbs, and nausea, somnolence, or dysgeusia with gepants. Postmarketing surveillance notes a hypertension signal with erenumab. Because CGRP supports physiologic vasodilation, prudence is warranted in patients with severe or unstable cardiovascular disease, though these agents themselves do not cause vasoconstriction. Data in pregnancy, lactation, and pediatrics remain limited; regulatory approvals are largely for adults. Gepants have drug–drug interaction considerations (e.g., CYP3A4), whereas mAbs have minimal pharmacokinetic interactions. In the broader treatment landscape, CGRP inhibitors compare favorably to traditional preventives (beta-blockers, topiramate, tricyclics) on tolerability and often on speed of benefit, though absolute efficacy gains are modest and costs higher. They can be combined with behavioral therapies, sleep optimization, trigger management, and, in select cases, onabotulinumtoxinA. Shared decision-making weighs attack frequency, prior treatment trials, comorbidities, patient preferences, route and frequency of administration, and access constraints.

Eastern and integrative traditions understand migraine as a disturbance of internal balance and flow affecting the head. Traditional Chinese Medicine (TCM) frequently identifies Liver yang rising with internal wind, sometimes compounded by phlegm-damp and blood stasis obstructing the channels that traverse the temples and vertex. Treatment principles calm wind, anchor yang, move blood, and clear heat, achieved through individualized acupuncture and herbal formulas. Ayurveda describes Ardhavabhedaka, often involving Vata (movement) and Pitta (heat) derangement, addressed through dietary cooling, routine and sleep regulation, stress reduction, nasal therapies (Nasya), and oil therapies (Shirodhara), alongside botanicals to steady the nervous system and digestion. Modern integrative science provides bridges between these frameworks and neurobiology. Acupuncture has moderate-quality evidence for reducing migraine frequency and disability, and small mechanistic studies show decreases in circulating CGRP and other pro-nociceptive mediators after treatment, aligning conceptually with the goal of calming “internal wind” and inflammation. Nutraceuticals such as magnesium (supporting neuronal stability), riboflavin (mitochondrial energy), and coenzyme Q10 (oxidative metabolism) have supportive evidence as preventive adjuncts and are often well tolerated. Mind–body approaches—biofeedback, relaxation training, mindfulness, and cognitive-behavioral therapy—modulate stress reactivity and autonomic tone, echoing traditional aims of restoring balance. When patients use CGRP inhibitors, integrative care focuses on complementarity: acupuncture and mind–body practices may reduce attack frequency and enhance resilience; sleep regularity, nutrition, and hydration address triggers; and selected botanicals or nutrients can be added with attention to interactions and patient-specific factors. Practitioners emphasize pattern differentiation (TCM) or dosha assessment (Ayurveda) to tailor nonpharmacologic strategies while coordinating with biomedical teams. Respecting that CGRP has physiologic roles, traditional practitioners also value gradual, balanced modulation of the pain system rather than aggressive suppression alone. The shared goal across traditions is fewer, less severe attacks and improved quality of life through a personalized blend of pharmacologic precision and holistic self-care.